Taysha Gene Therapies Inc (NASDAQ: TSHA) is 51.41% higher on its value in year-to-date trading and has touched a low of $0.50 and a high of $3.89 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TSHA stock was last observed hovering at around $2.72 in the last trading session, with the day’s loss setting it -0.04%.
Currently trading at $2.68, the stock is 0.83% and 19.47% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.88 million and changing -1.47% at the moment leaves the stock 39.11% off its SMA200. TSHA registered 248.05% gain for a year compared to 6-month gain of 4.28%. The firm has a 50-day simple moving average (SMA 50) of $26.99 and a 200-day simple moving average (SMA200) of -$3.96.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -4.29% loss in the last 1 month and extending the period to 3 months gives it a 58.58%, and is -15.46% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.50% over the week and 10.55% over the month.
Taysha Gene Therapies Inc (TSHA) has around 52 employees, a market worth around $501.21M and $15.45M in sales. Profit margin for the company is -722.06%. Distance from 52-week low is 436.00% and -31.11% from its 52-week high. The company has generated returns on investments over the last 12 months (-83.01%).
Taysha Gene Therapies Inc quarterly earnings per share for the current quarter are estimated at -$0.11 with sales reaching $2.13M over the same period.The EPS is expected to grow by 57.71% this year, but quarterly earnings will post -45.00% year-over-year. Quarterly sales are estimated to shrink -54.70% in year-over-year returns.
106 institutions hold shares in Taysha Gene Therapies Inc (TSHA), with institutional investors hold 92.71% of the company’s shares. The shares outstanding are 186.96M, and float is at 128.60M with Short Float at 12.30%. Institutions hold 69.75% of the Float.
The top institutional shareholder in the company is Vanguard Group Inc with over 1.59 million shares valued at $1.05 million. The investor’s holdings represent 0.85% of the TSHA Shares outstanding. As of Jun 29, 2023, the second largest holder is Tybourne Capital Management (HK) Limited with 1.5 million shares valued at $0.99 million to account for 0.80% of the shares outstanding. The other top investors are Artal Group S.A. which holds 1.44 million shares representing 0.77% and valued at over $0.95 million, while Nantahala Capital Management, LLC holds 0.67% of the shares totaling 1.25 million with a market value of $0.83 million.
Taysha Gene Therapies Inc (TSHA) Insider Activity
The most recent transaction is an insider purchase by Manning Paul B, the company’s 10% Owner. SEC filings show that Manning Paul B bought 100,000 shares of the company’s common stock on Nov 17 ’23 at a price of $1.63 per share for a total of $0.16 million. Following the purchase, the insider now owns 16.57 million shares.
Taysha Gene Therapies Inc disclosed in a document filed with the SEC on Aug 24 ’23 that Alam Kamran (Chief Financial Officer) sold a total of 33,000 shares of the company’s common stock. The trade occurred on Aug 24 ’23 and was made at $2.33 per share for $76890.0. Following the transaction, the insider now directly holds 0.26 million shares of the TSHA stock.
Still, SEC filings show that on Aug 16 ’23, Manning Paul B (10% Owner) acquired 16,466,667 shares at an average price of $0.90 for $14.82 million. The insider now directly holds 16,466,667 shares of Taysha Gene Therapies Inc (TSHA).
